395 million COVID vaccines said to have 50.4% efficacy. Now what?

by Web team (HR) | Jan 15, 2021 | COVID-19, News, Sheena Cruickshank

The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...

Why experts are warning against drinking alcohol when you have the vaccine

by Web team (HR) | Jan 12, 2021 | COVID-19, News, Sheena Cruickshank

The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...

COVID-19 immunity: how long does it last?

by Web team (HR) | Jan 11, 2021 | COVID-19, News, Sheena Cruickshank

The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...

Gut bacteria may influence severity of COVID complications, study suggests

by Web team (HR) | Jan 11, 2021 | COVID-19, Dan Davis, News

The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...

Are vaccination targets realistic?

by Web team (HR) | Jan 11, 2021 | COVID-19, News, Tracy Hussell

The Lydia Becker Institute of Immunology and Inflammation Research Barrier immunology Cancer immunology Cardiovascular immunology and multi-morbidities Cellular immunology Eco-immunology and context-specific immunology Immune tolerance Immuno-informatics Immuno-matrix...